UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 29, 2019
CATALYST PHARMACEUTICALS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
Delaware | 001-33057 | 76-0837053 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
355 Alhambra Circle Suite 1250 Coral Gables, Florida | 33134 | |||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (305)420-3200
Not Applicable
Former Name or Former address, if changed since last report
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17CFR240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Name of Exchange on Which Registered | Ticker Symbol | ||
Common Stock, par value $0.001 per share | NASDAQ Capital Market | CPRX |
Item 1.01 | Entry Into a Material Definitive Agreement |
On May 29, 2019, the Company and BioMarin Pharmaceutical Inc. (“BioMarin”) entered into that certain Amendment No. 2 to License Agreement (“theAmendment”), amending in certain respects the current License Agreement in place between BioMarin and the Company (the “License Agreement”) relating to Firdapse®.
Under the current License Agreement, the Company has licensed the rights to commercialize Firdapse® in North America. Under the Amendment, the Company’s commercial territory has been expanded to include Japan. Further, after the achievement of a certain milestone in Japan, the Company will have an option to further expand the commercial territory covered by its License Agreement to include most of Asia, as well as Central and South America.
Under the Amendment, the Company will pay royalties on net sales in Japan of a similar percentage to the royalties that the Company is currently paying under the original License Agreement for North America.
The Amendment is attached as Exhibit 10.1 to this Current Report on Form8-K and is incorporated herein by reference. Portions of the Agreement have been redacted pursuant to Item 601(b)(10) of RegulationS-K.
Item 8.01 | Other Events |
On May 30, 2019, the Company issued a press release announcing that it had entered into the Amendment. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form8-K and is incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Catalyst Pharmaceutical Partners, Inc. | ||
By: | /s/ Alicia Grande | |
Alicia Grande Vice President, Treasurer and CFO |
Dated: May 30, 2019